6OYT
ASK1 kinase domain in complex with GS-4997
Summary for 6OYT
| Entry DOI | 10.2210/pdb6oyt/pdb |
| Descriptor | Mitogen-activated protein kinase kinase kinase 5, 5-(4-cyclopropyl-1H-imidazol-1-yl)-2-fluoro-4-methyl-N-{6-[4-(propan-2-yl)-4H-1,2,4-triazol-3-yl]pyridin-2-yl}benzamide, ACETATE ION, ... (4 entities in total) |
| Functional Keywords | ask1 map3k5, transferase-transferase inhibitor complex, transferase/transferase inhibitor |
| Biological source | Homo sapiens (Human) |
| Total number of polymer chains | 4 |
| Total formula weight | 129121.81 |
| Authors | Marcotte, D.J. (deposition date: 2019-05-15, release date: 2019-11-27, Last modification date: 2023-10-11) |
| Primary citation | Himmelbauer, M.K.,Xin, Z.,Jones, J.H.,Enyedy, I.,King, K.,Marcotte, D.J.,Murugan, P.,Santoro, J.C.,Hesson, T.,Spilker, K.,Johnson, J.L.,Luzzio, M.J.,Gilfillan, R.,de Turiso, F.G. Rational Design and Optimization of a Novel Class of Macrocyclic Apoptosis Signal-Regulating Kinase 1 Inhibitors. J.Med.Chem., 62:10740-10756, 2019 Cited by PubMed Abstract: Structural analysis of a known apoptosis signal-regulating kinase 1 (ASK1) inhibitor bound to its kinase domain led to the design and synthesis of the novel macrocyclic inhibitor (cell IC = 1.2 μM). The profile of this compound was optimized for CNS penetration following two independent strategies: a rational design approach leading to and a parallel synthesis approach leading to . Both analogs are potent ASK1 inhibitors in biochemical and cellular assays (, cell IC = 95 nM; , cell IC = 123 nM) and have moderate to low efflux ratio (ER) in an MDR1-MDCK assay (, ER = 5.2; , ER = 1.5). In vivo PK studies revealed that inhibitor had moderate CNS penetration ( = 0.17) and analog had high CNS penetration ( = 1.0). PubMed: 31710475DOI: 10.1021/acs.jmedchem.9b01206 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (2.824 Å) |
Structure validation
Download full validation report
